Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

Tandem Diabetes Care Trading Up 1.2%

NASDAQ TNDM opened at $16.65 on Wednesday. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -17.90 and a beta of 1.66. The stock’s 50 day moving average price is $19.20 and its two-hundred day moving average price is $18.01. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. Tandem Diabetes Care, Inc. has a 52 week low of $12.26 and a 52 week high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The firm had revenue of $254.56 million during the quarter, compared to the consensus estimate of $254.99 million. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.78) EPS. As a group, analysts anticipate that Tandem Diabetes Care, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

Several institutional investors and hedge funds have recently bought and sold shares of the business. Leonteq Securities AG lifted its position in shares of Tandem Diabetes Care by 21.7% in the 1st quarter. Leonteq Securities AG now owns 9,501 shares of the medical device company’s stock worth $182,000 after buying an additional 1,695 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of Tandem Diabetes Care by 9.1% in the 1st quarter. Diversified Trust Co now owns 21,332 shares of the medical device company’s stock valued at $409,000 after buying an additional 1,774 shares during the period. OP Asset Management Ltd acquired a new position in shares of Tandem Diabetes Care in the 1st quarter valued at about $35,000. Integrated Wealth Concepts LLC bought a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at about $33,000. Finally, 180 Wealth Advisors LLC grew its position in shares of Tandem Diabetes Care by 17.3% during the 1st quarter. 180 Wealth Advisors LLC now owns 15,763 shares of the medical device company’s stock valued at $302,000 after buying an additional 2,320 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently commented on TNDM. Truist Financial cut their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a research report on Friday, August 7th. UBS Group began coverage on shares of Tandem Diabetes Care in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price for the company. William Blair initiated coverage on shares of Tandem Diabetes Care in a research note on Friday, August 21st. They issued an “outperform” rating on the stock. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $26.00 price target (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and an average price target of $27.08.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.